apremilast/Otezla®

Generic Name: apremilast
Drug Name: Otezla®

The list of clinical trials will be updated if additional studies are conducted, approved, and meet criteria for posting as explained in the Celgene Clinical Trial Data Sharing Policy.

Unique ID Indication / Disease Phase Study Name Synopsis
CC-10004-PSA-001
Alternate ID:
NCT00456092
EudraCT 2006-004619-23
Psoriatic Arthritis Phase 2 A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two dose regimens of  CC-10004 in subjects with active psoriatic arthritis  pdf_symbol
CC-10004-PSA-002
Alternate ID:
NCT01172938
EudraCT 2010-018385-23
Psoriatic Arthritis Phase 3 A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis  pdf_symbol
CC-10004-PSA-003
Alternate ID:
NCT01212757
EudraCT 2010-018386-32
Psoriatic Arthritis Phase 3 A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis  pdf_symbol
CC-10004-PSA-004
Alternate ID:
NCT01212770
EudraCT 2010-019941-24
Psoriatic Arthritis Phase 3 A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis and a qualifying psoriasis lesion  pdf_symbol
CC-10004-PSA-005
Alternate ID:
NCT01307423
EudraCT 2010-020324-22
Psoriatic Arthritis Phase 3 A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis who have not been previously treated with disease-modifying antirheumatic drugs  pdf_symbol
CC-10004-PSOR-001
Alternate ID:
NCT00604682
Plaque-type Psoriasis Phase 2 Open-label, single-arm pilot study to evaluate the pharmacodynamics, pharmacokinetics, safety, and preliminary efficacy of CC-10004 in subjects with severe plaque type psoriasis  pdf_symbol
CC-10004-PSOR-003
Alternate ID:
NCT00606450
EudraCT 2006-000057-22
Plaque-type Psoriasis Phase 2 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Comparison Study of CC-10004 in Subjects With Moderate-To-Severe Plaque-Type Psoriasis  pdf_symbol
CC-10004-PSOR-004
Alternate ID:
NCT00521339
Plaque-type Psoriasis Phase 2 A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of CC-10004 in Subjects With Recalcitrant Plaque-Type Psoriasis  pdf_symbol
CC-10004-PSOR-005
Alternate ID:
NCT00773734
Plaque-type Psoriasis Phase 2B A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)  pdf_symbol
CC-10004- PSOR-008
Alternate ID:
NCT01194219
EudraCT 2010-019991-55
Plaque-type Psoriasis Phase 3 A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis  pdf_symbol
CC-10004-PSOR-009
Alternate ID:
NCT01232283
EudraCT 2010-019992-30
Plaque-type Psoriasis Phase 3 A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis  pdf_symbol
CC-10004-RA-002
Alternate ID:
NCT01285310
2010-019926-15
Rheumatoid Arthritis Phase 2 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, to Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate  pdf_symbol
CC-10004-BCT-001
Alternate ID:
NCT00866359
Behçet Disease Phase 2 A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease  pdf_symbol
CC-10004-ASTH-001 Asthma Phase 2 A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Comparison, Parallel-Group, Exercise Challenge Study of CC-10004 in Subjects With Mild Asthma  pdf_symbol